Oct. 30 at 12:27 PM
$NERV NERV has a legitimate drug candidate and solid science, but the new funding deal brings heavy dilution that limits short-term upside. Even with a successful trial, which is still 18–24 months out, the stock will likely stay around
$10–15. If the trial fails, the downside could be rough, so while it’s a real company, the setup isn’t appealing right now.
